Strategic partnerships Abalos’ arenavirus-based immuno-oncology platform offers a differentiated mechanism that stimulates both innate and adaptive immunity against cancer. This positioning makes it attractive for pharma and biotechs seeking differentiated IO platforms for licensing or co-development deals, particularly for solid tumors and metastatic settings. Target outreach should prioritize large oncology franchises and mid-stage biotech companies looking to augment their pipelines with novel immune-oncology assets.

Manufacturing readiness As a lean biotech advancing viral-based therapeutics, Abalos may require GMP-grade manufacturing and scalable process development to support clinical trials. There is potential to engage CDMOs and contract manufacturing partners to accelerate scale-up, tech transfer, and supply chain readiness for Phase I/II studies.

EU funding options Based in Germany with a solid funding runway, Abalos could leverage EU grants and consortia for immuno-oncology research and development. Market BD opportunities include connecting the company with funding-focused partners or service providers skilled in grant writing, regulatory pathways, and EU clinical development collaborations.

Leadership signals Recent leadership appointments indicate readiness for strategic partnerships and external investment discussions. This makes early outreach to the CEO and senior management to explore licensing, milestone-based deals, or co-development opportunities more promising.

Market momentum The immuno-oncology space continues to grow, with patient demand for therapies that unleash multiple immune pathways. Abalos’ approach to activate precise innate and adaptive responses could attract collaborations around target indications with high unmet need and opportunities for early-stage trials, companion diagnostics, or payer engagement.